▲ +256.13% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Cyclo Therapeutics in the last 3 months. The average price target is $25.00, with a high forecast of $25.00 and a low forecast of $25.00. The average price target represents a 256.13% upside from the last price of $7.02.
The current consensus among 1 polled investment analysts is to buy stock in Cyclo Therapeutics.
Cyclo Therapeutics, Inc., a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in October 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.